Future Cardiol
-
Publication Venue For
- Vorapaxar in the treatment of cardiovascular diseases.. 16:373-384. 2020
- Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy.. 16:69-75. 2020
- The need for sex-specific precision biomarkers for antiplatelet therapies.. 13:419-422. 2017
- Drug delivery and therapeutic impact of extended-release acetylsalicylic acid.. 12:45-58. 2016
- Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.. 11:585-595. 2015
- Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.. 11:471-484. 2015
- Emerging role of contrast-enhanced MRI in diagnosing vascular malformations.. 10:479-486. 2014
- Platelet RNA as a novel biomarker for the response to antiplatelet therapy.. 10:9-12. 2014
- PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection.. 9:785-797. 2013
- Elinogrel: pharmacological principles, preclinical and early phase clinical testing.. 6:445-453. 2010
- REPAIR-AMI: stem cells for acute myocardial infarction.. 3:137-140. 2007
- Clinical implications of vulnerable plaque.. 2:721-731. 2006
- New therapeutic possibilities for vein graft disease in the post-edifoligide era.. 2:493-501. 2006
- Antiplatelet therapy: current strategies and future trends.. 2:343-366. 2006
- The African-American heart failure trial: a new look at old drugs.. 1:311-313. 2005
- Progenitor cell therapy of ischemic heart disease: the new frontier.. 1:87-98. 2005